Staff Profile
Gillian Watson
Trial Manager
- Email: gillian.watson@ncl.ac.uk
- Telephone: +44 (0) 191 208 8813
- Fax: +44 (0) 191 208 8901
- Address: Newcastle Clinical Trials Unit
Newcastle University
1-4 Claremont Terrace
Newcastle upon Tyne
NE2 4AE
Background
I am a Trial Manager, in the Newcastle CTU.
Research
I manage others' research, but do not lead on my own.
Teaching
I do not teach.
Publications
- Proctor SJ, Wilkinson J, Jones G, Watson GC, Lucraft HH, Mainou-Fowler T, Culligan D, Galloway MJ, Wood KM, McNally RJ, James PW, Goodlad JR. Evaluation of treatment outcome in 175 patients with Hodgkin lymphoma aged 60 years or over: the SHIELD study. Blood 2012, 119(25), 6005-6015.
- Proctor SJ, Wilkinson J, Culligan D, Galloway M, Lucraft HH, Jones G, Mcnally R, Wood KM, Mainou-Fowler T, Watson G, Goodlad JR. Comparative clinical responses of three chemotherapy schedules (VEPEMB, ABVD, CLVPP) in 175 Hodgkin Lymphoma patients over 60ys evaluated as part of the Shield (Hodgkin elderly) Study. In: Annals of Oncology: 11th International Conference on Malignant Lymphoma. 2011, Lugano, Switzerland: Oxford University Press.
- Murray AJ, Anderson RE, Watson GC, Radda GK, Clarke K. Uncoupling proteins in human heart. Lancet 2004, 364(9447), 1786-1788.
- Collie-Duguid ES, Johnston SJ, Powrie RH, Milano G, Etienne MC, Rochat B, Watson GC, McLeod HL. Cloning and initial characterization of the human DPYD gene promoter. Biochemical and Biophysical Research Communications 2000, 271(1), 28-35.
- Fisher A, Andreasson A, Chrysos A, Lally J, Mamasoula C, Exley C, Wilkinson J, Qian J, Watson G, Lewington O, Chadwick T, McColl E, Pearce M, Mann K, McMeekin N, Vale L, Tsui S, Yonan N, Simon A, Marczin N, Mascaro J, Dark J. An observational study of Donor Ex Vivo Lung Perfusion in UK Lung Transplantation : DEVELOP-UK. Health Technology Assessment 2016, 20(85).
- Watson G, O'Hara J, Carding P, Lecouturier J, Stocken D, Fouweather T, Wilson JA. TOPPITS: Trial Of Proton Pump Inhibitors in Throat Symptoms. Study protocol for a randomised controlled trial. BMC Trials 2016, 17, 175.
- Thomas K, Wright SE, Watson G, Baker C, Stafford V, Wade C, Chadwick TJ, Mansfield L, Wilkinson J, Shen J, Deverill M, Bonner S, Hugill K, Howard P, Henderson A, Roy A, Furneval J, Baudouin SV. Extra Physiotherapy in Critical Care (EPICC) Trial Protocol: a randomised controlled trial of intensive versus standard physical rehabilitation therapy in the critically ill. BMJ Open 2015, 5(5), e008035.
- Wilson JA, Stocken DD, Watson GC, Fouweather T, McGlashan J, MacKenzie K, Carding P, Karagama Y, Harries M, Ball S, Khwaja S, Costello D, Wood R, Lecouturier J, O'Hara J. A randomised, placebo controlled trial of extra-oesophageal reflux treatment in the management of upper respiratory symptoms.[TOPPITS:Trial of Proton Pump Inhibitors in Throat Symptoms]. Health Technology Assessment Journal 2021, 25(3), 1-118.
- Wright SE, Thomas K, Watson G, Baker C, Bryant A, Chadwick TJ, Shen J, Wood R, Wilkinson J, Mansfield L, Stafford V, Wade C, Furneval J, Henderson A, Hugill K, Howard P, Roy A, Bonner S, Baudouin S. Intensive versus standard physical rehabilitation therapy in the critically ill (EPICC): a multicentre, parallel-group, randomised controlled trial. Thorax 2018, 73(3), 213-221.
- Bourke JP, Watson G, Muntoni F, Spinty S, Roper H, Guglieri M, Speed C, McColl E, Chikermane A, Jayawant S, Adwani S, Willis T, Wilkinson J, Bryant A, Chadwick T, Wood R, Bushby K. Randomised placebo-controlled trial of combination ACE inhibitor and beta-blocker therapy to prevent cardiomyopathy in children with Duchenne muscular dystrophy? (DMD Heart Protection Study): a protocol study. BMJ open 2018, 8(12), e022572-.
- Abouhajar A, Alcock L, Bigirumurame T, Bradley P, Brown L, Campbell I, Del Din S, Faitg J, Falkous G, Gorman GS, Lakey R, McFarland R, Newman J, Rochester L, Ryan V, Smith H, Steel A, Stefanetti RJ, Su H, Taylor RW, Thomas NJP, Tuppen H, Vincent AE, Warren C, Watson G. Acipimox in Mitochondrial Myopathy (AIMM): study protocol for a randomised, double-blinded, placebo-controlled, adaptive design trial of the efficacy of acipimox in adult patients with mitochondrial myopathy. Trials 2022, 23(1), 789.
- Cheetham TD, Cole M, Abinun M, Allahabadia A, Barratt T, Davies JH, Dimitri P, Drake A, Mohamed Z, Murray RD, Steele CA, Zammitt N, Carnell S, Prichard J, Watson G, Hambleton S, Matthews JNS, Pearce SHS. Adjuvant Rituximab-Exploratory Trial in Young People With Graves Disease. Journal of Clinical Endocrinology and Metabolism 2022, 107(3), 743-754.
- Harding C, Mossop H, Homer T, Chadwick T, King W, Carnell S, Lecouturier J, Abouhajar A, Vale L, Watson G, Forbes R, Currer S, Pickard R, Eardley I, Pearce I, Thiruchelvam N, Guerrero K, Walton K, Hussain Z, Lazarowicz H, Ali A. Alternative to prophylactic antibiotics for the treatment of recurrent urinary tract infections in women: multicentre, open label, randomised, non-inferiority trial. BMJ 2022, 376, e068229.
- Harding C, Chadwick T, Homer T, Lecouturier J, Mossop H, Carnell S, King W, Abouhajar A, Vale L, Watson G, Forbes R, Currer S, Pickard R, Eardley I, Pearce I, Thiruchelvam N, Guerrero K, Walton K, Hussain Z, Lazarowicz H, Ali A. Methenamine hippurate compared with antibiotic prophylaxis to prevent recurrent urinary tract infections in women: the ALTAR non-inferiority RCT. Health Technology Assessment 2022, 26(23), 1-172.
- Wilson JA, Stocken DD, Watson GC, Fouweather T, McGlashan J, MacKenzie K, Carding P, Karagama Y, Harries M, Ball S, Khwaja S, Costello D, Wood R, Lecouturier J, O'Hara J. Lansoprazole for persistent throat symptoms in secondary care: the TOPPITS RCT. Health Technology Assessment 2021, 25(3), 1-118.
- Bourke JP, Watson G, Spinty S, Bryant A, Roper H, Chadwick T, Wood R, Mccoll E, Bushby K, Muntoni F, Guglieri M. Preventing Cardiomyopathy in DMD. Neurology: Clinical Practice 2021, 11(5), E661-E668.
- O'Hara J, Stocken DD, Watson GC, Fouweather T, McGlashan J, MacKenzie K, Carding P, Karagama Y, Wood R, Wilson JA. Use of proton pump inhibitors to treat persistent throat symptoms: multicentre, double blind, randomised, placebo controlled trial. British Medical Journal 2021, 372, m4903.